A 1.2 million € round A fundraising for Defymed opens the highway of MAILPAN’s development towards human trials
Posted on October 10, 2013Defymed announces today a fundraising of 1.2 million € together with its historical co-founder CeeD (Centre europeen d’etude du Diabete) and by welcoming the FLM (Fond Lorrain des Materiaux) among its shareholders. This first round comes to complete the series of Defymed’s sucess stories started since its foundation and will accelerate the development of the bioartificial pancreas MAILPAN towards the clinical trials in human.